Feed - Buzzberg

12:00
Jul 29 ◎

BSX FY2026 Q2 Watch

Boston Scientific Corporation (BSX) FY2026 Q2 Earnings Call

PEN BSX ▾

Mike Mahoney

The acquisition of Penumbra is expected to close in H2 2026, adding to BSX's cardiovascular product portfolio and strengthening long-term growth.

"We remain excited about the opportunity to add the Penumbra team in a highly differentiated and complementary portfolio to Boston Scientific."

PEN WATCH

Mike Mahoney

Management's guidance tone is clearly deteriorating due to expected continued pressure in EP and Watchman markets through 2027, leading to below-average growth and limited EPS expansion.

"While we are sharpening our forecasting processes and taking action to address controllable headwinds, our underlying assumptions are that these dynamics continue in 27, resulting in revenue growth below our WAMGR and limited adjusted EPS"

BSX WATCH

HIGH

12:00
Apr 22 ◎

BSX FY2026 Q1 Watch

Boston Scientific Corporation (BSX) FY2026 Q1 Earnings Call

PEN MDT JNJ ABT VALN.TA ▾

Mike Mahoney

The acquisition is on track to close, bringing a differentiated portfolio and a strong team to BSX.

"We remain excited about the opportunity to have the Penumbra team and highly differentiate portfolios at Boston Scientific."

PEN WATCH

Mike Mahoney

The US EP business (including PFA) is expected to be roughly flat to low single-digit growth for 2Q-4Q, a significant deceleration from historical performance, as BSX loses more share than anticipated to Medtronic, J&J, and Abbott. — This indicates that the US PFA competitive dynamic is shifting faster than expected, and BSX's leadership position is being challenged more intensely in the near term.

"Medtronic continues to be a solid competitor. J&J is enhancing their footprint in PFA, and Abbott at its early stages of launch in the U.S."

MDT WATCH JNJ WATCH ABT WATCH

John Monson

The closed acquisition adds a new commercial capability to BSX's urology franchise.

"We recently closed the acquisition of Valencia Technologies, which complements our urology business."

VALN.TA WATCH

Mike Mahoney

Management guided down full-year revenue and EPS growth, citing share loss in EP, decelerating standalone Watchman cases, and challenges in urology.

"This is a guide down that we quite frankly are not proud of, but we think it's the right thing to do and best reflects the current environment."

BSX WATCH

HIGH

13:00
Feb 04 ◎

BSX FY2025 Q4 Watch

Boston Scientific Corporation (BSX) FY2025 Q4 Earnings Call

SHL.DE PEN BSX MDT ABT ▾

Mike Mahoney

Partnership expands BSX's imaging portfolio in EP procedures; Siemens gains distribution through BSX's commercial channel.

"we announced a strategic partnership with Siemens Healthineers to develop and commercialize their next-generation 4D ice catheter called AccuNav"

SHL.DE WATCH

Mike Mahoney

Acquisition of Penumbra is expected to close in 2026, adding mechanical thrombectomy and neurovascular capabilities.

"Penumbra offers a highly differentiated portfolio that operates in high growth segments where Boston Scientific lacks offerings"

PEN WATCH

Mike Mahoney

Management maintains strong but moderated growth expectations, acknowledging market share loss in EP and transitory headwinds in Endo, while betting on diversified strength across other franchises.

"we expect our differentiated financial performance to continue in our guiding to organic growth of 8.5% to 10% for Q1 and 10% to 11% for the full year."

BSX WATCH

Mike Mahoney

US EP market penetrated ~70% with PFA in 2025; BSX expects market growth to normalize to ~15% in 2026, down from an estimated 18-20% in Q4 2025, with BSX explicitly planning to lose share due to competitive launches. — Signals the high-growth phase in US PFA is maturing; competitive share gains are expected to accelerate, pressuring all players on volume and pricing.

"we did anticipate that. And we are also very comfortable to say, as we looked at the end of 26, that we'll be the clear BFA market leader."

MDT WATCH ABT WATCH

Mike Mahoney

Intracept procedure received expanded reimbursement coverage, and BSX is launching the Intracept Edge Stylet to improve the treatment experience. — Expanded coverage and new tooling may accelerate adoption of basivertebral nerve ablation, potentially impacting competitors like SI-BONE.

"we received expanded reimbursement to coverage for the intracept procedure, initiated a full market launch of the Intracept Edge Stylet"

SIBNY WATCH

HIGH

Feed — Buzzberg